The rights to the technology and patents supporting the development of the current product line were acquired by BioElectronics in 2000. Prior to that time the previous owners of the technology and patents had invested over $4.65 million in electronic engineering prototypes, production runs, and in confirming clinical studies. BioElectronics subsequently filed with the US Food and Drug Administration for market clearance in April 2000.
The Company was granted its first approval from the FDA under a 510k in August 2002. Prior to FDA approval and the establishment of its research and development group, PAW, LLC (Andrew Whelan's wife and children) paid and expensed the cost of development.
In 2003, BioElectronics redesigned the ActiPatch product to reduce its size and costs to manufacture and developed several new products.
In March 2004, the Company sold 5,020,000 shares of common stock and the Company's stock was listed on the Pink Sheets. Currently the Company does not report to the Securities Exchange Commission.
In December 2004 the Company received ISO and CE (European Common Market) certification. In 2005 Health Canada, (Canada's FDA) approved ActiPatch Therapy: for the relief of pain in muscosketal complaints.
In April 2005, the Company established an Orthopedic Group, a direct response sales organization, and its design and manufacturing operations in Westlake Village, California.
In 2007 the Company shut down the Orthopedic Group, moved all operations to the home office and transferred manufacturing offshore.
In early 2008 the Company redesigned its product, manufacturing and established new disease specific products and distinct medical and retail product lines. It also shifted its attention to international sales.
The Company was granted its first approval from the FDA under a 510k in August 2002. Prior to FDA approval and the establishment of its research and development group, PAW, LLC (Andrew Whelan's wife and children) paid and expensed the cost of development.
In 2003, BioElectronics redesigned the ActiPatch product to reduce its size and costs to manufacture and developed several new products.
In March 2004, the Company sold 5,020,000 shares of common stock and the Company's stock was listed on the Pink Sheets. Currently the Company does not report to the Securities Exchange Commission.
In December 2004 the Company received ISO and CE (European Common Market) certification. In 2005 Health Canada, (Canada's FDA) approved ActiPatch Therapy: for the relief of pain in muscosketal complaints.
In April 2005, the Company established an Orthopedic Group, a direct response sales organization, and its design and manufacturing operations in Westlake Village, California.
In 2007 the Company shut down the Orthopedic Group, moved all operations to the home office and transferred manufacturing offshore.
In early 2008 the Company redesigned its product, manufacturing and established new disease specific products and distinct medical and retail product lines. It also shifted its attention to international sales.